Trifluridine–tipiracil for previously treated metastatic colorectal cancer

  • Technology appraisal guidance
  • TA405
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 Trifluridine–tipiracil is recommended, within its marketing authorisation, as an option for treating metastatic colorectal cancer, that is:

  • in adults who have had previous treatment with available therapies including fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents, or when these therapies are not suitable, and

  • only when the company provides trifluridine–tipiracil with the discount agreed in the patient access scheme.